Screener
Arcus Biosciences RCUS Total Liabilities & Equity
Total Liabilities & Equity at other companies
Other financials
Where this comes from
Reported directly by Arcus Biosciences in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesAndStockholdersEquity.
The source filing: Arcus Biosciences’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 4:11 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001724521-26-000044
| Line item | June 30,2026 | December 31,2025 |
|---|---|---|
| Other noncurrent liabilities | 124 | 135 |
| Commitments | ||
| Stockholders’ equity: | ||
| Common stock and additional paid-in capital: $0.0001 par value per share; 400.0 shares authorized; 127.0 shares in 2026 and 125.3 shares in 2025 issued and outstanding | 2,169 | 2,116 |
| Accumulated deficit | (1,704) | (1,485) |
| Accumulated other comprehensive loss | (1) | — |
| Total stockholders’ equity | 464 | 631 |
| Total liabilities and stockholders’ equity | $924 | $1,139 |
Item 1. Financial Statements
FAQ
- What is Arcus Biosciences's total liabilities & equity?
- Arcus Biosciences (RCUS) reported total liabilities & equity of $924M in Q2 2026.
- How has Arcus Biosciences's total liabilities & equity changed year-over-year?
- Arcus Biosciences's total liabilities & equity decreased by 14.0% year-over-year, from $1.08B to $924M.
- What is the long-term trend for Arcus Biosciences's total liabilities & equity?
- Over 5 years (2020 to 2025), Arcus Biosciences's total liabilities & equity has grown at a 8.1% compound annual growth rate (CAGR), from $772.29M to $1.14B.
- What does total liabilities & equity mean?
- Total assets = total liabilities + total equity. This must always balance — a fundamental accounting identity.
Ask your AI about Arcus Biosciences's total liabilities & equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude